Li Gong

Li Gong

Auto-generated profile, based on publicly available information

Li Gong

Department of Biomedical Data Science Stanford University Stanford California USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
PDF file
JLJoshua P Lewis
Joshua P Lewis
JBJoshua D Backman
Joshua D Backman
JRJean-Luc Reny
Jean-Luc Reny
TBThomas Bergmeijer
Thomas Bergmeijer
BMBraxton Mitchell
Braxton Mitchell
FIfor the ICPC Investigators
for the ICPC Investigators
Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants have clinical utility to predict major adverse cardiovascular events (CVEs) remains controversial. We assessed the impact of 31 candidate gene polymorphisms on adenosine diphosphate (ADP)-stimulated platelet reactivity in 3391 clopidogrel-treated coronary artery disease patients of the International Clopidogrel Pharmacogenomics Consortium (ICPC). The influence of these polymorphisms on CVEs was tested in 2134 ICPC patients (N = 129 events) in whom clinical event data were available. Several variants were associated with on-treatment ADP-stimulated platelet reactivity (CYP2C19*2, P = 8.8 × 10−54; CES1 G143E, P = 1.3 × 10−16; CYP2C19*17, P = 9.5 × 10−10; CYP2B6 1294 + 53 C > T, P = 3.0 × 10−4; CYP2B6 516 G > T, P = 1.0 × 10−3; CYP2C9*2, P = 1.2 × 10−3; and CYP2C9*3, P = 1.5 × 10−3). While no individual variant was associated with CVEs, generation of a pharmacogenomic polygenic response score (PgxRS) revealed that patients who carried a greater number of alleles that associated with increased on-treatment platelet reactivity were more likely to experience CVEs (β = 0.17, SE 0.06, P = 0.01) and cardiovascular-related death (β = 0.43, SE 0.16, P = 0.007). Patients who carried eight or more risk alleles were significantly more likely to experience CVEs [odds ratio (OR) = 1.78, 95% confidence interval (CI) 1.14–2.76, P = 0.01] and cardiovascular death (OR = 4.39, 95% CI 1.35–14.27, P = 0.01) compared to patients who carried six or fewer of these alleles. Several polymorphisms impact clopidogrel response and PgxRS is a predictor of cardiovascular outcomes. Additional investigations that identify novel determinants of clopidogrel response and validating polygenic models may facilitate future precision medicine strategies.

27 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
LGLi Gong
Li Gong
SLSeung‐Been Lee
Seung‐Been Lee
JWJonathan B. Wagner
Jonathan B. Wagner
XZXujia Zhou
Xujia Zhou
AGAndrea Gaedigk
Andrea Gaedigk

18 July 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KCKelly E Caudle
Kelly E Caudle
MWMichelle Whirl-Carrillo
Michelle Whirl-Carrillo
MRMary V. Relling
Mary V. Relling
JHJames M. Hoffman
James M. Hoffman
RDRoseann S. Donnelly
Roseann S. Donnelly
TKTeri E. Klein
Teri E. Klein

3 January 2025 in Clinical Chemistry
Verified
Journal Article
Closed access
LGLi Gong
Li Gong
CKClarissa J Klein
Clarissa J Klein
KCKelly E Caudle
Kelly E Caudle
Ann MoyerAnn Moyer
Ann Moyer
SSStuart A Scott
Stuart A Scott
C(ClinGen Pharmacogenomics Working Group (PGxWG)
ClinGen Pharmacogenomics Working Group (PGxWG)
Pharmacogenomics (PGx) is focused on the relationship between an individual's genetic makeup and their response to medications, with the overarching aim of guiding prescribing decisions to improve drug efficacy and reduce adverse events. The PGx and genomic medicine communities have worked independently for over 2 decades, developing separate standards and terminology, making implementation of PGx across all areas of genomic medicine difficult. To address this issue, the Clinical Genome Resource (ClinGen) Pharmacogenomics Working Group (PGxWG) was established by the National Institutes of Health (NIH)-funded ClinGen to initially create frameworks for evaluating gene–drug response clinical validity and actionability aligned with the ClinGen frameworks for evaluating monogenic gene–disease relationships, and a framework for classifying germline PGx variants similar to the American College of Medical Genetics (ACMG) and Association of Molecular Pathology (AMP) system for interpretation of disease-causing variants. These frameworks will leverage decades of work from well-established PGx resources facilitating buy-in among PGx stakeholders. In this report, we describe the background and major activities of the ClinGen PGxWG, and how this initiative will facilitate the critical inclusion of PGx into the larger context of genomic medicine.

27 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GYGuang Yang
Guang Yang
CACristina Alarcon
Cristina Alarcon
CCCatherine Chanfreau
Catherine Chanfreau
NLNorman H. Lee
Norman H. Lee
PFPaula Friedman
Paula Friedman
MPMinoli A. Perera
Minoli A. Perera
Clopidogrel, an anti‐platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and transcriptome data. We conducted a genome‐wide association study (GWAS), including local ancestry adjustment, in 141 AA on clopidogrel to identify genetic associations with high on‐treatment platelet reactivity (HTPR), with validation of genome‐wide significant and suggestive loci in an independent cohort of AA clopidogrel patients (N = 823) from the Million Veteran's Program (MVP) along with in vitro functional analysis. We performed differential gene expression (DGE) analysis in whole blood to identify transcriptomic predictors of response, followed by functional validation in MEG‐01 cells. GWAS identified one signal on Chromosome 7 as significantly associated with increasing risk of HTPR. The lead single‐nucleotide polymorphism (SNP), rs7807369, within thrombospondin 7A (THSD7A) was associated with an increased risk of HTPR (odds ratio (OR) = 4.02, P = 4.56 × 10−9). Higher THSD7A gene expression was associated with HTPR in an independent cohort of clopidogrel‐treated patients (P = 0.004) and carrying a risk allele showed increased gene expression in primary human endothelial cells. Notably, the CYP2C19*2 variants showed no association with clopidogrel response in the discovery or MVP cohorts. DGE analysis identified an association with decreased LAIR1 and AP3B2 expression to HTPR. LAIR1 knockdown in MEG‐01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. In summary, these findings suggest that other variants and genes outside of CYP2C19 star alleles play an important role in clopidogrel response in AA.

11 September 2020 in Genes
Verified
Journal Article
Open access
PDF file
TBThomas Bergmeijer
Thomas Bergmeijer
AYAlfi Yasmina
Alfi Yasmina
GVGerrit J. A. Vos
Gerrit J. A. Vos
PJPaul W. A. Janssen
Paul W. A. Janssen
CHChristian M. Hackeng
Christian M. Hackeng
VDVera H.M. Deneer
Vera H.M. Deneer
This study aims to determine whether genetic variants that influence CYP3A4 expression are associated with platelet reactivity in clopidogrel-treated patients undergoing elective percutaneous coronary intervention (PCI), and to evaluate the influence of statin/fibrate co-medication on these associations. A study cohort was used containing 1124 consecutive elective PCI patients in whom CYP3A4*22 and PPAR-α (G209A and A208G) SNPs were genotyped and the VerifyNow P2Y12 platelet reactivity test was performed. Minor allele frequencies were 0.4% for CYP3A4*22/*22, 6.8% for PPAR-α G209A AA, and 7.0% for PPAR-α A208G GG. CYP3A4*22 was not associated with platelet reactivity. The PPAR-α genetic variants were significantly associated with platelet reactivity (G209A AA: −24.6 PRU [−44.7, −4.6], p = 0.016; A208G GG: −24.6 PRU [−44.3, −4.8], p = 0.015). Validation of these PPAR-α results in two external cohorts, containing 716 and 882 patients, respectively, showed the same direction of effect, although not statistically significant. Subsequently, meta-analysis of all three cohorts showed statistical significance of both variants in statin/fibrate users (p = 0.04 for PPAR-a G209A and p = 0.03 for A208G), with no difference in statin/fibrate non-users. In conclusion, PPAR-α G209A and A208G were associated with lower platelet reactivity in patients undergoing elective PCI who were treated with clopidogrel and statin/fibrate co-medication. Further research is necessary to confirm these findings.